. >> foot locker is a name that karen finerman has loved so much she put it in her 2023 acronym now what >> very difficult day, obviously. there was a lot to hate about this earnings release. you know, mary dillon talked about softer demand, this was an accommodation softer demand and discretionary spending by the consumer getting weaker, but also it was promotional for them the revenue miss wasn't that bad. the bottom line miss was terrible and they were just as promotional as they could be and i don't think that's abating at all, which is why the rest of the guidance for the year was so bad. one other thing, they're not going to be giving guidance going forward. they didn't want to cut that come turkey, so they did give guidance for the rest of the year, which was dismal they cited left the, like others have, but that wasn't the problem. it was the activity. and didn't sound like traffic was really getting better. >> sounded like it was getting worse. >> i didn't hear that it was getting worse. i didn't hear that it was getting better, though and so it's troubling that this was a very

patel, it's karen finerman thank you for being on i wonder drugs like this, with a price tag that's goingrage, and with sort of -- it's sort of a 35% delay, to what exactly -- what kind of coverage do you expect, what kind of push-back to you expect to get on coverage here >> yeah, karen, this is -- look, this is my old kind of policy backyard, thinking about medicare coverage, and this is -- right now, on the biogen, they have what is called coverage with evidence development, meaning there's kind of a limited and restricted cov coverage this generated blowback from the patient community and some clinical members of the community that say it deserved a much broader coverage, meaning a national coverage determination without those kind of parameters that limit the coverage. this lilly study is going to put them in an interesting position. they are going to have to look at this data, the full packet of data that the fda is looking at, and it seems incredibly compelling they should expand coverage and take away that coverage with evidence determination. just given what we saw with -- as, to

lee, this is "fast money" live from the nasdaq market site on the desk tonight, tim see your, karen finerman, dan nathan, and guy adaadami. president biden meeting at the white house with congressional leaders. they've been at it for just under an hour. the white house pool was in the oval office. the president said he wouldn't take any questions, and ignored reporters asking him and house speaker mccarthy if they would cut a deal to prevent a debt default. investors on edge. the major averages closing the day slightly lower the dow now down six of the last seven sessions let's get more on today's meeting and the behind the scenes wrangling on the debt ceiling from nbc white house monica alba. >> that's right, courtney. the white house and the president firm, they don't want to be negotiating at all when it comes to raising the debt ceiling. they believe is co this is congress's constitutional duty. so, this is a meeting that, of course, is taking place face-to-face and significant in the fact that it is occurring, because for weeks now, the white house has said they didn't want to come toge